Cargando…
Blood Endothelial-Cell Extracellular Vesicles as Potential Biomarkers for the Selection of Plasma in COVID-19 Convalescent Plasma Therapy
Despite the advancement of vaccination and therapies currently available, deaths due to the coronavirus disease 2019 (COVID-19) are still heavily documented. Severely infected individuals experience a generalized inflammatory storm, caused by massive secretion of pro-inflammatory cytokines that can...
Autores principales: | Amri, Nada, Tessier, Nolwenn, Bégin, Rémi, Vachon, Laurent, Bégin, Philippe, Bazin, Renée, Loubaki, Lionel, Martel, Catherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563445/ https://www.ncbi.nlm.nih.gov/pubmed/36231083 http://dx.doi.org/10.3390/cells11193122 |
Ejemplares similares
-
Use of Early Donated COVID-19 Convalescent Plasma Is Optimal to Preserve the Integrity of Lymphatic Endothelial Cells
por: Amri, Nada, et al.
Publicado: (2022) -
Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset
por: Perreault, Josée, et al.
Publicado: (2020) -
The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
por: Ullah, Irfan, et al.
Publicado: (2022) -
Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine
por: Tessier, Nolwenn, et al.
Publicado: (2021) -
Lipid metabolism of plasma-derived small extracellular vesicles in COVID-19 convalescent patients
por: Xiao, Wenjing, et al.
Publicado: (2023)